Cellogen Therapeutics announced that it has received around $2 million in a round of funding on January 17, 2024. The transaction included participation from new investor, NATCO Pharma Limited.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
987.4 INR | -0.26% | +0.24% | +21.69% |
08/05 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
08/05 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.69% | 2.09B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- NATCOPHARM Stock
- News NATCO Pharma Limited
- Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited